This post was originally published on this site
In addition, with surging chronic diseases around the globe, the pharmaceuticals sector is expected to grow significantly. According to a Markets and Markets report, the global pharmaceutical drug delivery market is expected to reach $2.21 trillion by 2026, growing at a 5.9% CAGR.
Therefore, we think it could be wise to add fundamentally sound yet undervalued pharmaceutical stocks GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Limited (NYSE:TEVA), and Eagle Pharmaceuticals, Inc. (EGRX) to one’s portfolio now. These stocks have an overall A (Strong Buy) or B (Buy) grade in our POWR Ratings system. They also have an A grade for Value.
